Bain leads big $70M round as Aptinyx plunges deeper into NMDA work
Two years after Aptinyx spun out of Naurex in the wake of Allergan’s $560 million buyout, the biotech is much further along in the pipeline than your average fledgling. It just tacked on a hefty $70 million B round to beef up the work and drive deeper toward a pivotal phase of development. And the new kid on the VC block, Bain Capital Life Sciences, jumped out to lead the round, with managing director Adam Koppel joining the board.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.